Journal article
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
- Abstract:
-
BACKGROUND: In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational studies, larger increases in many different AEs have been reported than in blinded trials.
METHODS: In the Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial, patients aged 40-79 years with hypertension, at least three other cardiovascular risk factors, and fasting total cholesterol concentrations of 6·5 mmol/L or lower...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 388.9KB, Terms of use)
-
- Publisher copy:
- 10.1016/S0140-6736(17)31075-9
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet More from this journal
- Volume:
- 389
- Issue:
- 10088
- Pages:
- 2473-2481
- Publication date:
- 2017-05-02
- Acceptance date:
- 2017-02-22
- DOI:
- EISSN:
-
1474-547X
- ISSN:
-
0140-6736
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:695813
- UUID:
-
uuid:b53478e9-9cc0-4aca-9461-2794a39b8c3f
- Local pid:
-
pubs:695813
- Source identifiers:
-
695813
- Deposit date:
-
2017-06-12
- ARK identifier:
Terms of use
- Copyright holder:
- © 2017 Elsevier Ltd All rights reserved
- Copyright date:
- 2017
- Notes:
- This is the author accepted manuscript following peer review version of the article. The final version is available online from Elsevier at: 10.1016/S0140-6736(17)31075-9
If you are the owner of this record, you can report an update to it here: Report update to this record